February 13, 2026 11:03 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
BJP MP files notice to cancel Rahul Gandhi's Lok Sabha membership, seeks life-long ban | Arrested in the morning, out by evening: Tycoon’s son walks free in Lamborghini crash case | ‘Why should you denigrate a section of society?’: Supreme Court pulls up ‘Ghooskhor Pandat’ makers | Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six
Sinopharm
WIKIMEDIA COMMONS

China's Sinopharm COVID-19 vaccine safe and efficacious: WHO official

| @indiablooms | May 12, 2021, at 06:28 pm

Geneva/UNI: China's Sinopharm COVID-19 vaccines, very much used globally, have been considered both safe and efficacious, according to Mariangela Simao, World Health Organization (WHO) assistant director general for access to health products.

"We still have data proving that they are efficacious against severe disease," she said in a press conference on Monday. "Sinopharm has been very much used globally. I think 62 million doses have already been applied. It has been considered both safe and efficacious."

WHO Director-General Tedros Adhanom Ghebreyesus announced last week that China's Sinopharm COVID-19 vaccine has been validated for emergency use, marking the first Chinese vaccine officially recognized by the WHO.

The approval came after an extensive review by an external, technical advisor group that looked at different data, Simao added.

"We did site inspections in China in January and February... We accessed the clinical data available for Sinopharm. It was also considered suitable, and (with) efficacy and safety in good manufacturing practice," she noted.

She also mentioned that the WHO is committed to the COVAX Facility, which is "an equitable access mechanism that we are very much working on and striving to get enough doses to be distributed."

The official called for a change in the code of behavior, as many vaccine producers "are moving towards a profit-driven approach instead of an equitable-access approach."

"So (the) WHO is pushing very hard at the highest level for everyone who is manufacturing vaccines to consider putting those vaccines in a global mechanism that will ensure that all countries have access to them, not only high-income countries who can pay more for the vaccines, as we are seeing as we speak right now," Simao said.

"The code of behavior, when you talk about it, is not for vaccine nationalism. It is for everyone who has a product that can be a public health good and can help us in this acute phase of this pandemic," she stressed.

 

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.